Generate Biomedicines reported earnings of -$ 0.68 per GENB share on Nov 12, 2026, beating analysts' expectations by
| Report Date | Nov 12, 2026 |
|---|---|
| Forecasted EPS | -$ 0.56 |
| Earnings Per Share (Surprise) | -$ 0.68 (-$ 0.12) |
Out of the last 2 earnings reporting periods, Generate Biomedicines beat analysts’ expectations 0 times and fell short of expectations 2 time(s). Generate Biomedicines reported earnings per share of -$ 0.68 in the last report falling to reach an estimated EPS of -$ 0.56 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.56 | -$ 0.68 | - | - |
| Aug 6, 2026 | -$ 0.51 | -$ 0.52 | - | - |
Generate Biomedicines’s stock was trading at $ 13.49 on Nov 11, 2026 a day before the last earnings report was released.Following the release of the earnings report, GENB’s price decreased to $ 12.07 on Nov 13, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 12, 2026 | -$ 0.68 | $ 13.49 | $ 12.07 | |
| Aug 6, 2026 | -$ 0.52 | $ 14.49 | $ 14.35 |
Generate Biomedicines released its most recent earnings reports in November 2026, August 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Generate Biomedicines missed analysts’ expectations during the last earnings period by
